louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06240156: A Study on Plantar Pressure Distribution, Gait Balance and Lower Back Pain in Pregnant Women
Official title: Effect of Insole Intervention on Plantar Pressure Distribution, Gait Balance and Lower Back Pain in Flatfoot Women During the Third Trimester
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Low Back Pain
Keywords: pregnancy, gait balance, foot pain, lower back pain
Lead sponsor: National Taipei University of Nursing and Health Sciences
Sponsor class: OTHER
First posted: 2024-02-02
Enrollment: 85
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study was to understand women with low arched feet, flat feet, or BMI\> 29 in the third trimester.

Detailed description: The purpose of this study was to understand women with low arched feet, flat feet, or BMI\> 29 in the third trimester. Compare the intervention measures of different foot pads immediately, two weeks, four weeks, and six weeks after the intervention Immediate and long-term benefits in relief of plantar pressure, dynamic and static balance, and lower back pain.

Eligibility criteria: Inclusion Criteria:

* able to understand and write Chinese
* health and third trimester women
* low arched feet or flat feet or BMI\> 29

Exclusion Criteria:

* Women with a medical record of back, foot, ankle, knee, musculoskeletal, or neuromuscular trauma or disease

Primary outcomes:
measure: plantar pressure
timeFrame: footpad intervention measures immediately, two weeks, four weeks, six weeks after intervention
measure: static balance
timeFrame: footpad intervention measures immediately, two weeks, four weeks, six weeks after intervention
measure: foot pain
timeFrame: footpad intervention measures immediately, two weeks, four weeks, six weeks after intervention
measure: lower back pain
timeFrame: footpad intervention measures immediately, two weeks, four weeks, six weeks after intervention
measure: daily life disturbance scales
timeFrame: footpad intervention measures immediately, two weeks, four weeks, six weeks after intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Wan-Lin Pan
Study officials:
affiliation: professor
name: Meei-Ling Gau, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06979856: Short, Animated Storytelling (SAS) Video to Reduce Smartphone Addiction in the US
Official title: Short, Animated Storytelling Video to Reduce Smartphone Addiction in the US: Protocol for an Online, Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Smartphone Addiction
Keywords: Addictive Behavior
Smartphone addiction
screen time
digital well-being
mental health
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2025-05-20
Enrollment: 6000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study will test the effect of a short, animated storytelling video on participants' perceived risk of smartphone overuse immediately after exposure and two weeks later.


Eligibility criteria: Inclusion Criteria:

* English Speaking
* Own a Smartphone
* Live in the US

Exclusion Criteria:

* None

Primary outcomes:
measure: Smartphone Addiction Scale (SmAS) score
timeFrame: Baseline, immediate post-intervention and 2 weeks post intervention
Secondary outcomes:
measure: Average compensation acceptable to participants (in theory) to stop using smartphone for 1 day
timeFrame: Baseline, Immediate post-intervention (upto 24 hours), 2 weeks post intervention
measure: 24 hour smartphone use time
timeFrame: Baseline, 2 weeks post intervention
measure: Perceived danger of excessive smartphone use scale score
timeFrame: Baseline, immediate post-intervention (upto 24 hours) and 2 weeks post exposure
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University
state: California
Study officials:
affiliation: Stanford University
name: Maya U Adam, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02810756: Study With Improved Solubility Pazopanib
Official title: Proof of Principle and Pharmacological Phase 0 Study With Improved Solubility Pazopanib
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Pharmacokinetics of Pazopanib
Lead sponsor: The Netherlands Cancer Institute
Sponsor class: OTHER
First posted: 2016-06-23
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The pharmacokinetics of a new formulation with Pazopanib will be studied. This will be done in a patient cohort of n = 12.


Eligibility criteria: Inclusion Criteria:

* Locally advanced or metastatic cancer;
* Able and willing to give written consent;
* WHO performance status of 0, 1 or 2;
* Able and willing to undergo blood sampling for PK analysis;
* Minimal acceptable safety laboratory values;
* Negative pregnancy test for female patients with childbearing potential;
* Able and willing to swallow oral medication.

Exclusion Criteria:

* Any treatment with investigational drugs within 30 days prior to receiving the investigational treatment;
* Any treatment with CYP3A4, BCRP or PGP interfering drugs;
* Patients who received treatment with Votrient(R) kess than 1 week ago;
* Woman who are pregnant or breast feeding;
* Patients suffering from any known condition that may influence the dissolution or absorption of Pazopanib.

Primary outcomes:
measure: Plasma concentration
timeFrame: 24 hours
Secondary outcomes:
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
timeFrame: 1 week
measure: Area under the plasma concentration versus time curve (AUC)
timeFrame: 24 hours
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Netherlands Cancer Institute
state: North Holland
Study officials:
References:
Clinical trial NCT01825356: Amniotic Membrane as an Adjunct Treatment for Hallux Rigidus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hallux Rigidus
Lead sponsor: OrthoCarolina Research Institute, Inc.
Sponsor class: OTHER
First posted: 2013-04-05
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether patients undergoing a dorsal cheilectomy procedure with implementation of amniotic membrane tissue results in improved clinical and functional outcomes compared to a standard dorsal cheilectomy procedure.

Specific Aim 1:

To compare American Orthopedic Foot and Ankle Society (AOFAS) scores between patients undergoing dorsal cheilectomy to patients undergoing dorsal cheilectomy with implantation of amniotic membrane tissue.

Hypothesis 1: Clinical and functional outcomes, as measured by the AOFAS , in the patients undergoing dorsal cheilectomy with implantation of amniotic membrane tissue will be superior to those without.

Specific Aim 2:

To compare range of motion between patients undergoing dorsal cheilectomy to patients undergoing dorsal cheilectomy with implantation of amniotic membrane tissue.

Hypothesis 2: Patient to undergo dorsal cheilectomy and implantation of amniotic membrane tissue will demonstrate less postoperative stiffness as measured from the pre-and postoperative radiographs.

Specific Aim 3:

To compare Foot Function Index (FFI) scores between patients undergoing dorsal cheilectomy to patients undergoing dorsal cheilectomy with implantation of amniotic membrane tissue.

Hypothesis 3: Clinical and functional outcomes, as measured by the FFI, the patients undergoing dorsal cheilectomy with implantation of amniotic membrane tissue will be superior to those without.


Eligibility criteria: Inclusion Criteria:

* Patients presented with an isolated diagnosis of type II hallux rigidus who are candidates for operative management with dorsal cheilectomy.
* Patients over the age of 18 able to consent to participate
* The subject is psychosocially, mentally, and physically able to understand and comply with the requirements of the study

Exclusion Criteria:

* \< 18 years of age
* Patients that use ambulatory assistive devices
* Patients with systemic inflammtory arthritis
* Patient undergoing revision surgery for hallux rigidus to the ipsilateral extremity
* Patients with significant arthritis requiring alternative surgery other than dorsal cheilectomy

Primary outcomes:
measure: American Orthopedic Foot and Ankle Society (AOFAS) score
timeFrame: 6 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Charlotte
country: United States
facility: OrthoCarolina
state: North Carolina
Study officials:
affiliation: OrthoCarolina Research Institute, Inc.
name: John K Ellington, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03285256: Effects of Repeated Memory Training on Memory Function and Addiction Related Processes
Official title: Effects of Repeated Memory Training on Memory Function and Addiction Related Processes
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Substance-Related Disorders
Keywords: Prospective memory, working memory, substance abuse
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2017-09-15
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be randomly assigned to one of three treatment conditions: an experimental memory training program or one of two comparator memory training programs.
Primary purpose: TREATMENT

Brief summary: Prospective memory is the ability to implement an intention to the future (e.g. remember to take medication, attend a scheduled meeting), and has receive little attention in addiction. The investigators propose that prospective memory plays a critical, yet unrecognized, role in major human behavior change such as that required in addiction treatment. This study will determine the preliminary efficacy of prospective memory training in improving memory and executive functions while reducing illicit drug use in methadone patients. Participants will be randomly assigned to one of three conditions: an experimental memory training program or one of two comparator memory training programs.


Eligibility criteria: Inclusion Criteria:

* Age 18-55; provision of written consent
* Enrolled in a substance use treatment program
* Sex with ≥ 2 partners in the last 30 days and sex without a condom on at least one occasion in the last year

Exclusion Criteria:

* Severe psychiatric conditions associated with psychosis or any unstable psychiatric condition
* History of medical, psychiatric, or neurological conditions associated with significant cognitive impairment

Primary outcomes:
measure: Change in prospective memory over course of training
timeFrame: one month
measure: Change in drug use and substance abuse over course of training.
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins University School of Medicine, Bayview Campus
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Matthew W Johnson, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00911456: Can 3D Ultrasound Be Used Reproducibly by Radiation Therapists in Partial Breast Image-Guided Radiation Therapy
Official title: Can 3D Ultrasound Be Used Reproducibly by Radiation Therapists in Partial Breast Image-Guided Radiation Therapy?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Radiation Therapy for Primary Breast Cancer
Lead sponsor: British Columbia Cancer Agency
Sponsor class: OTHER
First posted: 2009-06-02
Enrollment: 27
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine if the Clarity 3DUS (3D Ultrasound) system can be used by multiple individuals to acquire 3DUS images and produce consistent TB (Tumor Bed) shifts for breast IGRT (Image-Guided Radiation Therapy).

Detailed description: TB Contouring The CT1, CT2, and US1 tumor beds will be manually contoured on the RM workstation by one of the study radiation therapists. Contouring will be performed using previously defined contouring guidelines. Available automatic contouring tools, including the 'interpolate' contouring function, may be utilized and contouring times will be recorded.

IGRT Assessment The patient will be set up on the breast board in treatment position. The 'ultra path' component of the Clarity system, which displays the path of the previous US acquired at CT simulation, will be used to guide the acquisition of US2. Although performed in the simulator room, the Clarity system will be used in 'treatment mode' thus simulating Clarity as it is used for IGRT. The study RT will first acquire the US2 scan. All steps following the acquisition of US2 will be performed off-line on the RM workstation without the need for further simulator or patient time.

Eligibility criteria: Inclusion Criteria:

* Subjects will be 27 consenting women undergoing CT simulation for adjuvant breast radiotherapy at VIC ≤16 weeks after BCS.
* Women must have primary tumors \<3cm, pathologically N0 disease, and negative surgical margins.
* Seroma clarity score \<2

Exclusion Criteria:

* Patients will be excluded if they have had mastectomy or receive adjuvant chemotherapy that results in the CT simulation session occurring \>16 weeks after the BCS date.

Primary outcomes:
measure: Will the Clarity of breast IGRT product have the potential to improve localization through its ability to compare 3DUS at the time of planning to 3DUS at the time of treatment.
timeFrame: Outcome will be measured three times during the 3DUS
Secondary outcomes:
Other outcomes:
Locations:
city: Victoria
country: Canada
facility: BC Cancer Agency Vancouver Island BCCA
state: British Columbia
Study officials:
affiliation: British Columbia Cancer Agency
name: Tanya Berrang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05191056: Anti-aging and Anti-oxidant Efficacy Evaluation of the MelaGene
Official title: Anti-aging and Anti-oxidant Efficacy Evaluation of the MelaGene
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aging
Antioxidative Stress
Lead sponsor: TCI Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2022-01-13
Enrollment: 51
Sex: ALL
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary purpose of the present study is to evaluate the effects of MelaGene on anti-aging and anti-oxidant.


Eligibility criteria: Inclusion Criteria:

* 30 to 65-year-old;
* Must read and sign the informed consent form before the experiment;
* People who are willing to cooperate with contraception during the trial period;
* Do not change lifestyle and eating habits arbitrarily during the trial period;
* Do not take supplementary foods and health supplements with the same efficacy two weeks before and during the test;
* If any adverse reaction occurs during the experiment, subjects should be notified the researcher immediately.

Exclusion Criteria:

* Subject who is not willing to participate in this study;
* Vegetarians;
* People with a history of organ transplantation, epilepsy or convulsions, liver and kidney disease, malignant tumors, endocrine diseases, mental illness, alcohol or drug abuse, and other major organic diseases (according to medical history);
* Participate in other clinical trials related to antioxidants and anti-aging four weeks before and during the test;
* People with a history of dyspepsia would affect the absorption of the test product;
* Allergic to the components of the test product;
* Pregnant or breast-feeding women;
* Take anti-oxidant supplements;
* Undergoing hormone replacement therapy.

Primary outcomes:
measure: The change of blood lipid (Triglyceride, total cholestrol, HDL-C, LDL-C)
timeFrame: Days 1, 28, and 56
measure: The change of ALT and AST
timeFrame: Days 1, 28, and 56
measure: The change of MDA
timeFrame: Days 1, 28, and 56
measure: The change of blood antioxidants(f-Thiols, t-GSH, GST-RBC, SOD, Total Anit-oxidative Capicity)
timeFrame: Days 1, 28, and 56
measure: The change of anti-aging gene expression
timeFrame: Days 1, 28, and 56
measure: The change of cardiovascular endurance
timeFrame: Days 1, 28, and 56
Secondary outcomes:
measure: The change of continuous attention test
timeFrame: Days 1, 28, and 56
measure: The change of fatigue condition
timeFrame: Days 1, 28, and 56
Other outcomes:
Locations:
city: Pingtung
country: Taiwan
facility: Bo Han Wu
Study officials:
affiliation: Pingtung University of Science and Technology
name: Bo han Wu, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06160856: Correlation of Ultrasonography Indices of Venous Congestion With Intra-abdominal Pressure in ICU Patients.
Official title: Correlation of Ultrasonography Indices of Venous Congestion With Intra-abdominal Pressure in ICU Patients.
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Intra-Abdominal Hypertension
Venous Congestion
Lead sponsor: National and Kapodistrian University of Athens
Sponsor class: OTHER
First posted: 2023-12-07
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Consecutive adult patients admitted in a 31-bed University-affiliated general ICU in a tertiary hospital (Evangelismos General Hospital, Athens, Greece). The ICU admitts both medical and surgical patients.

Brief summary: The goal of this prospective observational study is to examine the potential association between intra-abdominal pressure and venous congestion as assessed by abdominal ultrasound, in critically ill patients in the Intensive Care Unit (ICU).

The main question it aims to answer is whether there is association between intra-abdominal pressure and Venous Excess Ultrasound (VExUS) score.

Participants will be sonographically assessed and their intra-abdominal pressure measured once within the first 3 days of ICU admission.


Eligibility criteria: Inclusion Criteria:

* Intubated ICU patients on controlled mechanical ventilation, receiving sedation. Patients must have urethral catheter in place.

Exclusion Criteria:

* age \< 18 year old
* pregnancy / lactation
* primary liver disease (hepatic cirrhosis, hepatic space-occupying lesions, Budd-Chiari syndrome, portal vein thrombosis) or hepatic surgery
* end stage renal failure or on chronic dialysis
* non-intubated patients or intubated patients on non-controlled mechanical ventilation mode
* absence of urethral catheter, presence of suprapubic catheter, continuous bladder irrigation
* poor abdominal echogenicity

Primary outcomes:
measure: VExUS score difference between the 2 study groups (normal and elevated intra-abdominal pressure)
timeFrame: 01.12.2023 - 01.08.2024
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00481156: Functional Neuroimaging Effects of Cognitive Remediation Training
Official title: Functional Neuroimaging Effects of Cognitive Remediation Training
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Schizophrenia
Lead sponsor: University of Minnesota
Sponsor class: OTHER
Collaborators: name: Minnesota Medical Foundation
First posted: 2007-06-01
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized, placebo-controlled, single-blind. An untreated healthy control group was also included to examine simple retest effects.
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to examine behavioral and functional brain changes occuring as a result of cognitive remediation training in patients with schizophrenia. Extension and specificity of related changes will also be examined.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of schizophrenia or schizoaffective disorder
* Stable outpatient

Exclusion Criteria:

* Current drug abuse or dependence
* History of neurological damage, disorder, or disease

Primary outcomes:
measure: Working Memory performance
timeFrame: Post-test
measure: Brain activation
timeFrame: Post-test
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Angus W MacDonald, Ph.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Minnesota
name: Kelvin O Lim, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Haut KM, Lim KO, MacDonald A 3rd. Prefrontal cortical changes following cognitive training in patients with chronic schizophrenia: effects of practice, generalization, and specificity. Neuropsychopharmacology. 2010 Aug;35(9):1850-9. doi: 10.1038/npp.2010.52. Epub 2010 Apr 28.